Breaking News, Financial News

Financial Report: Baxter 2Q11

BioScience revenues top $1.6 billion, driven by Gammagard demand.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Baxter 2Q11 2Q Revenues: $3.5 billion (+11%) 2Q Earnings: $615 million (+15%) YTD Revenues: $6.8 billion (+11%) YTD Earnings: $1.2 billion (earnings were $472 million YTD10) Comments: BioScience revenues were up 14% to $1.6 billion (up 10% excluding the impact of foreign currency), driven by demand for Gammagard Liquid, certain specialty plasma-based therapeutics, and vaccines. Medical Products sales were up 8% to $2.0 billion in the quarter, reflecting growth of anesthesia products, nutrit...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters